

**From:** Greenfeder, Scott [mailto:scott.greenfeder@merck.com]  
**Sent:** Tuesday, January 14, 2014 11:39 AM  
**To:** Rivers, Katie  
**Cc:** Valenti, Elizabeth  
**Subject:** RE: Information Request for BLA125478/0

Dear Katie,

Please see the attached in response to the below information request.

Regards,  
Scott

**Scott Greenfeder, Ph.D.**

Director and Liaison  
Global Regulatory Affairs  
T: +1 732-594-1021  
Fax: +1 732-594-1030  
[scott.greenfeder@merck.com](mailto:scott.greenfeder@merck.com)

Merck Research Labs  
126 East Lincoln Ave.  
MS RY33-204  
Rahway, NJ 07065  
[www.merck.com](http://www.merck.com)

**From:** Rivers, Katie [mailto:Katie.Rivers@fda.hhs.gov]  
**Sent:** Friday, January 10, 2014 1:50 PM  
**To:** Greenfeder, Scott  
**Cc:** Valenti, Elizabeth  
**Subject:** Information Request for BLA125478/0

Dear Scott,

Please provide the number of subjects who received RAGWITEK across all dosage strengths per age group listed in the table below.

Age (years)	RAGWITEK All dosage strengths N = 1707	RAGWITEK 12 Amb a 1-U N = 1057	Placebo N = 757
18-49	1405	841	590
50-83	302	216	167
50-64		194	153
65-74		17	12
75-83		5	2

Please let me know if you have any questions.

Thank you,

Katie

Katie H. Rivers, MS

Regulatory Project Manager, CMC1

FDA/CBER/OVRR/DVRPA

1401 Rockville Pike, HFM-481

Rockville, MD 20852

Phone 301-796-2640

Fax 301-827-3877

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.